Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX(NASDAQ:CRNX) SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 62,475 shares of its common stock and granted an aggregate of 43,800 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
CRNXSAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH). Atumelnant is the first and only small molecule ACTH receptor antagonist in clinical development.
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNXSAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit (“RSU”) awards to 27 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals To Present Research On Paltusotine, Atumelnant And Unmet Needs In Acromegaly Treatment
CRNXCrinetics Pharmaceuticals Q1 EPS $(1.04) Misses $(0.93) Estimate, Sales $361.00K Beat $90.91K Estimate
CRNXCrinetics Pharmaceuticals Receives EMA Validation of Marketing Authorization Application And Orphan Drug Designation For Paltusotine In Acromegaly
CRNXJP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics' Atumelnant Data
CRNXJP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions. Analysts see long-term potential.
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology
CRNXStifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.
Stifel Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces Price Target of $60
CRNXCitizens Capital Markets Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $91
CRNXCrinetics Pharmaceuticals Q4 GAAP EPS $(0.88), Inline
CRNXCrinetics Pharmaceuticals Appoints Tobin Schilke As Chief Financial Officer, Effective February 28th, 2025
CRNXHC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $81 Price Target
CRNXCrinetics Pharmaceuticals Announced Topline Results From Phase 2 Study Of Atumelnant For Classic Congenital Adrenal Hyperplasia And Adrenocorticotropic Hormone-dependent Cushing's Syndrome
CRNXCitigroup Maintains Buy on Crinetics Pharmaceuticals, Raises Price Target to $74
CRNXCrinetics Pharmaceuticals Announces ENDO 2024 Late-Breaking Abstracts; Were Released Earlier Than The Previously Announced Embargoed Date; More Fulsome Data Set Will Be Shared Within The Poster Presentations Scheduled To Be Presented On June 3, 2024
CRNXCrinetics Pharmaceuticals's Return On Capital Employed Overview
CRNXBenzinga Pro data, Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q2 sales of $439 thousand. Earnings fell to a loss of $42.38 million, resulting in a 22.38% decrease from last quarter.
